Latest MGuard(TM) Stories
TEL AVIV, Israel, May 17, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) mesh protective stent system, today announced that it has filed its Form 10-Q for the three months ended March 31, 2011 with the U.S.
PARIS, May 16, 2011 /PRNewswire/ -- InspireMD, Inc. (OTCBB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) mesh protective stent system, will partake in the EuroPCR conference this week.
TEL AVIV, Israel, May 5, 2011 /PRNewswire/ -- InspireMD, Inc.
TEL AVIV, Israel, March 2, 2011 /PRNewswire/ -- InspireMD, developer of the MGuard(TM) net protective stent system, has expanded its MGuard production facilities to meet the steady increase in demand.
TEL AVIV, Israel, December 17, 2010 /PRNewswire/ -- InspireMD, developer of the novel MGuard(TM), a combination of a coronary stent merged with an embolic protection specifically designed for Acute MI (AMI) patients, received significant exposure at the ICI, Innovations in Interventional Cardiology, meeting this week in Tel-Aviv.
SAN FRANCISCO, September 23 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr.
BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial).
- Withering but not falling off, as a blossom that persists on a twig after flowering.